Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · June 20, 2013

6 vs 12 Months of Adjuvant Trastuzumab in HER2+ Early Breast Cancer

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
6 Months Versus 12 Months of Adjuvant Trastuzumab for Patients With HER2-Positive Early Breast Cancer (PHARE): A Randomised Phase 3 Trial
Lancet Oncol 2013 Jun 11;[EPub Ahead of Print], X Pivot, G Romieu, M Debled, J-Y Pierga, P Kerbrat, T Bachelot, A Lortholary, M Espié, P Fumoleau, D Serin, J-P Jacquin, C Jouannaud, M Rios, S Abadie-Lacourtoisie, N Tubiana-Mathieu, L Cany, S Catala, David Khayat, I Pauporté, A Kramar

Further Reading